Pfizer Beats Estimates, Reaffirms Outlook on New Products

Pfizer reported first-quarter financial results that exceeded Wall Street analyst estimates, posting adjusted EPS of 75 cents and revenue of $14.45 billion. The company reaffirmed its long-term outlook, citing growth from newer products and strategic investments. To offset declining sales from older drugs and COVID-related products, Pfizer highlighted its $10 billion acquisition of Metsera. Furthermore, the company is focusing significant attention on upcoming late-stage clinical trial data for a targeted lung cancer drug.

Pfizer announced first-quarter earnings and revenue that surpassed Wall Street expectations, underpinned by growth in newer products and strategic acquisitions.

Q1 Financial Performance vs. Estimates

According to data compiled from analyst surveys by LSEG, Pfizer reported strong first-quarter figures compared to market predictions:

Adjusted Earnings Per Share (EPS): Reported at 75 cents, exceeding the expected 72 cents.
Revenue: Reached $14.45 billion, surpassing the anticipated $13.79 billion.

Strategy for Future Growth

The pharmaceutical company is strategically pivoting to bolster its revenue streams against declining sales from older and COVID-related products. This strategy centers on:

Long-Term Pipeline Investments: Focusing on growth from its drug development pipeline.
Acquisitions: Completing a recent $10 billion acquisition of the obesity biotech firm, Metsera.
Clinical Data Focus: Closely monitoring key data releases throughout the year, particularly late-stage trial results for a novel, targeted drug designed for lung cancer treatment.